WAM
ELTX icon

Warberg Asset Management’s Elicio Therapeutics ELTX Stock Holding History

Warberg Asset Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,801
Closed -$48.5K – 223
2024
Q2 		$48.5K Buy
+11,801
New +$99.8K 0.01% 149

Other funds holding ELTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Warberg Asset Management's ELTX Position: Q3 2024 in Review

Warberg Asset Management sold out of Elicio Therapeutics (ELTX) in Q3 2024, closing a stake of 11,801 shares — an estimated $48.5K sold.

Warberg Asset Management first reported a position in ELTX in Q2 2024 and held it in 1 quarter. The position peaked at $48.5K in Q2 2024. 18 funds tracked by Wall St. Rank hold ELTX as of Q3 2024.

  • Warberg Asset Management reported no remaining Elicio Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Warberg Asset Management sold 11,801 Elicio Therapeutics shares in Q3 2024, an estimated $48.5K.
  • Warberg Asset Management first reported a position in Elicio Therapeutics in Q2 2024 and held it in 1 quarter.
  • Warberg Asset Management's Elicio Therapeutics position peaked at $48.5K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2024.

Based on Warberg Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.